PuSH - Publication Server of Helmholtz Zentrum München: The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Ohnmacht, A. ; Stahler, A.* ; Stintzing, S.* ; Modest, D.P.* ; Holch, J.W.* ; Westphalen, C.B.* ; Hölzel, L. ; Schübel, M.K. ; Galhoz, A. ; Farnoud, A. ; Ud-Dean, M. ; Vehling-Kaiser, U.* ; Decker, T.* ; Moehler, M.* ; Heinig, M. ; Heinemann, V.* ; Menden, M.P.

The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer.

Nat. Commun. 14:5391 (2023)

Publ. Version/Full Text

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

Precision medicine has revolutionised cancer treatments; however, actionable biomarkers remain scarce. To address this, we develop the Oncology Biomarker Discovery (OncoBird) framework for analysing the molecular and biomarker landscape of randomised controlled clinical trials. OncoBird identifies biomarkers based on single genes or mutually exclusive genetic alterations in isolation or in the context of tumour subtypes, and finally, assesses predictive components by their treatment interactions. Here, we utilise the open-label, randomised phase III trial (FIRE-3, AIO KRK-0306) in metastatic colorectal carcinoma patients, who received either cetuximab or bevacizumab in combination with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI). We systematically identify five biomarkers with predictive components, e.g., patients with tumours that carry chr20q amplifications or lack mutually exclusive ERK signalling mutations benefited from cetuximab compared to bevacizumab. In summary, OncoBird characterises the molecular landscape and outlines actionable biomarkers, which generalises to any molecularly characterised randomised controlled trial.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Folfiri Plus Cetuximab; Consensus Molecular Subtypes; Dna Topoisomerase-i; Subgroup Identification; Wild-type; Microsatellite Instability; Predictive Biomarkers; 1st-line Treatment; Open-label; Chemotherapy

ISSN (print) / ISBN 2041-1723

e-ISSN 2041-1723

Journal Nature Communications

Quellenangaben Volume: 14, Issue: 1, Article Number: 5391

Publisher Nature Publishing Group

Publishing Place London

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Computational Biology (ICB)

Grants European Research Council (ERC)
Roche Pharma AG, Grenzach, Germany
Almac Ltd, Belfast, UK
Pfizer GmbH, Germany
Merck KGaA, Darmstadt, Germany
European Research Council (ERC) under the European Union
This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. 950293, M.P.M.). The clinical study received industrial funding from Merck KGaA, Darm